Added executives bring years of industry expertise to the company as Aetion continues to invest in future growth
NEW YORK, November 8, 2022 /PRNewswire/ — Aetion, the global leader in real-world evidence (RWE) technology and analytics, today announced the appointments of Professor Dorothee Bartels as Chief Digital Officer, Jade Cusick as commercial director, and Jeremy Brody as Chief Strategy Officer. Together, they will accelerate Aetion’s momentum in serving life sciences customers, regulators and payers in United States and Europe.
“At this pivotal time of growing demand for real-world evidence, Dorothee, Jade and Jeremy bring unparalleled healthcare expertise and business acumen to Aetion’s leadership team,” said Caroline Magill, CEO of Aetion and Member of the Board of Directors. “Their background demonstrates a passion for using data and analytics to unite stakeholders in improving patient health outcomes.”
Trained as an epidemiologist, Bartels has led global teams in implementing thoughtful and innovative real-world evidence (RWE) solutions that emphasize impact and scalability. She has held leadership positions in epidemiology and digital innovation at UCB and Boehringer-Ingelheim and was responsible for clinical and real data strategy for X, the Moonshot Factory.
Recognized as one of the most inspiring leaders in life sciences in 2021 by PharmaVOICE, Cusick has dedicated his career to finding client-centered solutions to the toughest problems in healthcare. Most recently, Cusick served as Global Head of Customer Partnership and Commercialization at Cerner Enviza, a division of Oracle, and prior to that he was instrumental in the growth of Kantar Health.
Brody is known for the business transformations he led at Kantar Health and Cerner and for seeing possibilities where others cannot. As a leader in business development and innovation, he has forged partnerships that have resulted in significant business growth and patient value.
“We’re starting to see accelerating progress in using real-world evidence to expand what we know about drugs and how they’re used to benefit patients,” said Dr. Scott Gottlieb, former Commissioner of the United States Food and Drug Administration and member of the Board of Directors of Aetion. “Aetion’s real-world evidence technology and expertise is well-suited to deliver on the promise of real-world data to expand insights into safe drug use that will lead to better outcomes for health.”
Aetion is a healthcare analytics company that provides real-world evidence to manufacturers, buyers, and regulators of medical technologies and treatments. The Aetion Evidence Platform® analyzes real-world data to produce transparent, timely and scientifically validated answers on safety, efficacy and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion illuminates healthcare’s most critical decisions – what works best, for whom, and when – to guide the product development, marketing and payment innovation. Learn more about aetion.com and follow us on @aetioninc.